Yuen, Penumbra CFO, sells $500k in shares

Penumbra Inc. (NASDAQ:PEN) Chief Financial Officer Maggie Yuen sold 2,000 shares of common stock on August 13, 2025, at a price of $250.0, totaling $500,000. The sale was executed under a Rule 10b5-1 trading plan. The medical devices company, currently valued at $9.8 billion, trades at a P/E ratio of 66, reflecting premium market positioning. According to InvestingPro analysis, the stock appears overvalued at current levels, despite maintaining a "GREAT" financial health score.

On August 15, 2025, Yuen also exercised options to acquire 724 shares of Penumbra’s common stock at $158.30, for a total value of $114,609.

Following these transactions, Yuen directly owns 13,667 shares of Penumbra, a portion of which are subject to vesting, and includes 86 shares purchased under the company’s Employee Stock Purchase Plan. She also holds 5376 stock options.

In other recent news, Penumbra Inc. reported its second-quarter 2025 earnings, surpassing both earnings per share (EPS) and revenue estimates. The company achieved an EPS of $0.86, exceeding the anticipated $0.83, and recorded a revenue of $339.5 million, above the expected $327.77 million. Following these results, UBS raised its price target on Penumbra to $335 from $330, maintaining a Buy rating, citing solid growth. Similarly, RBC Capital adjusted its price target to $325 from $330, maintaining an Outperform rating, despite a slightly lowered margin outlook. Penumbra also raised its 2025 revenue guidance, attributing this to strong growth in its peripheral vascular segment and above-market performance in its stroke business. These developments highlight the company’s robust performance and optimistic future projections by analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.